NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Inflammasome Therapeutics

Inflammasome Therapeutics

Private
Newton, MassachusettsHealthcare & Life Scienceshttps://inflam.com/

Last Round

Seed Round

May 4, 2026

Total Funding Raised

$3.22M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Inflammasome Therapeutics is a biotechnology company that develops therapies for prevalent, degenerative diseases such as Alzheimer's, multiple sclerosis, and macular degeneration by preventing aberrant inflammasome activation.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

inflammasome inhibitorsdrug discoverybiotechnologysmall molecule therapeuticsocular drug deliverychronic inflammationneurodegenerative diseaseinvestigational new drugINDpreclinical developmentbiotech pipelinedrug licensingpharma partneringinflammasome biologytherapeutic modality

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Inflammasome Therapeutics Comparables

Compare Inflammasome Therapeutics with similar companies based on industry and business-model similarity.

Inflammasome Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
NodThera
89%
Halia Therapeutics
88%
IFM Therapeutics
87%

Inflammasome Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Seed RoundMay 4, 2026
GrantMay 1, 2025
Seed RoundJan 26, 2024
GrantAug 9, 2021
GrantSep 16, 2020
Strategic
Sep 20, 2019

Key People

Founding team and executive leadership

Marty Nazzaro

Chief Operating Officer

Executive Team

Inflammasome Therapeutics Investors

Notable investors and investment history

Inflammasome Therapeutics investors
InvestorRounds
Boehringer IngelheimStrategic
Gates FoundationGrant
Bill & Melinda Gates FoundationGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 27, 2026

    Grew 125% QoQ, from 4 to 9 employees.

  • May 4, 2026

    $13.16M raised in Seed Round.

Inflammasome Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Inflammasome Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Inflammasome Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersNewton, Massachusetts
Employee Range9
Year Founded2016
Last FundingMay 4, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.